Unlike conventional pulmonary embolism, PTTM is driven by cytokine-mediated vascular remodeling, particularly involving platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), which trigger endothelial activation, intimal thickening, and microvascular obstruction [2]. The gene discussed is VEGFA; the disease is pulmonary embolism.